Skip to main content Skip to footer

Algernon Pharmaceuticals Inc.

  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Pipeline
    • Overview
    • NP-120 (Ifenprodil)
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Mar 31, 2021 8:00am EDT

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

Mar 29, 2021 7:02am EDT

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

Mar 17, 2021 7:00am EDT

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Mar 11, 2021 7:41am EST

Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

Mar 05, 2021 7:31pm EST

Algernon Pharmaceuticals Announces Increase and Close of Private Placement

Mar 03, 2021 8:00am EST

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Mar 02, 2021 10:18pm EST

Algernon Pharmaceuticals Announces Private Placement

Mar 01, 2021 8:00am EST

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Mar 01, 2021 7:00am EST

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

Feb 25, 2021 7:00am EST

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • …Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap